A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Talacotuzumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 23 Nov 2017 Planned End Date changed from 1 Feb 2019 to 26 Sep 2019.
    • 23 Nov 2017 Planned initiation date changed from 1 Oct 2016 to 30 Jun 2017.
    • 23 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top